Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
Serum and CSF S100B, neuron specific enolase,
      and tau protein in acute encephalopathy with
       biphasic seizures ...
Vous avez terminé ce document.
Télécharger et lire hors ligne.
Prochain SlideShare
Bilden av min verksamhet grovskiss3
  • Soyez le premier à aimer ceci

Icncaoccn 2012 poster shiihara t

  1. 1. Serum and CSF S100B, neuron specific enolase, and tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion Takashi Shiihara , Mio Watanabe , Keiko Kamayachi , Noriko Sawaura 1 1 2 2 Gunma Children’s Medical Center, Gunma, Japan ; Gunma University 1 Graduate School of Medicine, Gunma, Japan 2 Introduction Results In the early stages of the disease, The levels of all biomarkers were acute encephalopathy with biphasic significantly higher in AESD than seizures and late reduced diffusion those of FS patients (table 1). (AESD) could resemble its far more When only days 0 to 2 samples Table 1: Clinical characteristics and prevalent and benign counterpart, from AESD patients were used, the biomarkers in FS and AESD. AESD patients febrile seizure (FS), but often are shown as the all patients and the patients levels of all the measured results in some neurological with day 0-2 samples available. biomarkers, except serum NSE, sequelae. were still significantly higher in Biomarkers, such as S100B, patients with AESD than those in neuron-specific enolase (NSE), and FS. Conclusions tau protein, have been regarded CSF S100B (cut-off value, 100 AESD may be associated with as damage marker of astrocytes, pg/ml) and CSF tau protein (cut-off damage to astrocytes, neurons neurons, and axons, respectively. value, 100 pg/ml) were better and axons, even in the early predictors of AESD compared to stages of the disease. CSF S100B other biomarkers (fig. 1). and tau levels can be helpful for Aim early diagnosis. To assess whether serum and Combining both CSF S100B and cerebrospinal fluid (CSF) S100B, CSF tau levels maximized the NSE, and tau protein are altered in sensitivity (71.4%) plus AESD and to evaluate their specificity (94.7%) of the test to References diagnostic validity. distinguish AESD from FS. The positive predictive value for Takanashi J, et al. Neurology AESD was 83.3% (fig. 2). 2006;66:1304-9. Methods Tanuma N, et al. Brain Dev 2010;32:435-9. We measured and compared serum and CSF S100B, NSE, and tau protein levels in 43 patients with FS and 18 patients Acknowledgements with AESD, using sandwich enzyme-linked immunosorbent This study was supported by the assays, at any point during their Medical Research Program of Fig. 1: ROC curves for serum (left) and CSF illness. Ethics approval was (right) biomarkers (solid line: S100B; dashed Gunma Prefectural Government, obtained from the institutional line: NSE; dotted line: tau protein). AUCs Japan. We are deeply grateful to all review board. are noted along the line. the patients, their parents, and the Fig. 2: Scatter plot doctors who participated in this  To assess early diagnostic showing the study. validity, we analyzed these relationships between biomarkers in 43 FS patients and CSF S100B and tau Apart from this study, we Japan are 8 AESD patients, for whom day 0 protein in AESD still struggling after the disaster (closed circle) and FS to 2 samples were available. (open circle). Vertical- March 11, 2011. We are grateful and horizontal-dashed for the world help. Arigatou!!  We used the receiver operating lines denote cut-off characteristic (ROC) curve with values for AESD, CSF S100B and tau protein the area under curve (AUC) to (all 100 pg/ml). evaluate the diagnostic values of these markers.



Nombre de vues


Sur Slideshare


À partir des intégrations


Nombre d'intégrations









Mentions J'aime